We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Watson To Pay Elan $18M To Settle Naprelan IP Suit

Law360 (March 9, 2009, 12:00 AM EDT) -- Watson Pharmaceuticals Inc. will pay $18 million to Elan Corp. PLC to settle patent litigation over Watson's generic version of Naprelan, or naproxen sodium tablets, Watson announced Friday.

The company will not market or sell its product until Elan's patent on the drug expires in 2014 or is found invalid or unenforceable, according to a Watson statement.

Friday's settlement resolves three patent infringement suits and an antitrust case between Watson and Elan, according to James Monroe, a partner at Finnegan Henderson Farabow Garrett & Dunner LLP,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.